Eden Research Plc · LSE:EDEN
Eden Research — 15 months to 31 March 2026 Earnings Presentation
25 slides from Eden Research's earnings presentation, August 2026
Slide 1: 2026 preliminary results presentation
Biopesticide pioneer Plant-derived, residue-free active ingredients 33 countries 2026 preliminary Product authorisations globally results presentation 130 patents Granted and pending The only UK AIM-quoted company focused on plant-derived biopesticides for sustainable agriculture. >6 commercial part
Slide 2: Eden occupies a unique position as the UK's only AIM-quoted biopesticide innovator
COMPANY Eden occupies a unique position as the UK's only AIM-quoted biopesticide innovator Core capabilities span plant-derived chemistry, plastic-free encapsulation and a growing global regulatory footprint. 33 ~100 130 £19m+ Countries with Crop use Granted & Invested in IP & product authorisation
Slide 3: 2025/26 Commercial and operational highlights
COMPANY 2025/26 Commercial and operational highlights Strong commercial and operational progress made in the 15 months to 31 March 2026 • Approval of flagship fungicide product, Mevalone®, for the control of powdery mildew on grapes in California. • Ecovelex was granted temporary approval in Italy (
Slide 4: 2025/26 Commercial and operational highlights (continued)
COMPANY 2025/26 Commercial and operational highlights (continued) Strong commercial and operational progress made in the 15 months to 31 March 2026 • Appointment of Andermatt Kenya as the Company's exclusive distribution partner for Mevalone in Kenya. • Agreement with Veto-pharma, a French pharmaceu
Slide 5: 2025/26 Financial highlights and post period end
COMPANY 2025/26 Financial highlights and post period end Strong sales in the period and strong balance sheet following £10.8m (gross) fundraise around the period end Financial highlights • Revenue for the period was £4.9 million (CY2024: £4.3 million) • Operating loss for the period was £2.9 million
Slide 6: Upcoming news flow
COMPANY Upcoming news flow Key upcoming milestones due for the rest of the financial year to 31 March 2027 • AGM 29 Sept. 2026 • Emergency use applications for Ecovelex Q3 2026 • Full approval of Ecovelex in Europe 2026 • Commercial agreement(s) for insecticide 2026 • New distribution agreement(s) f
Slide 7: A commercial portfolio built on plant-derived, residue-free chemistry
PRODUCTS A commercial portfolio built on plant-derived, residue-free chemistry Using Eden's proprietary Sustaine® encapsulation platform — polymer-free, solvent-free, approved for organic use Mevalone® Cedroz Ecovelex Insecticide Biofungicide · Commercial Bionematicide · Commercial Seed treatment ·
Slide 8: Sustaine technology delivers six structural advantages over conventional and competing biochemistries
PRODUCTS Sustaine® technology delivers six structural advantages over conventional and competing biochemistries Product characteristics that support market access, grower adoption, and premium positioning 'Residue free' Polymer-free formulation Solvent-free, stable Exempt from pesticide residue limi
Slide 9: A phased pipeline from early discovery to commercial launch across four product categories
PIPELINE A phased pipeline from early discovery to commercial launch across four product categories Three products commercial or in registration; three pipeline products in active development Product / Target Crops / Markets Discovery Early Dev Late Dev Partners Status Mevalone® Corteva · Syngenta H
Slide 10: Mevalone has a €582m addressable market and a new €2.4bn downy mildew opportunity
MEVALONE® Mevalone® has a €582m addressable market — and a new €2.4bn downy mildew opportunity Regulatory approvals in 33 countries, with Brazil, South Africa and Argentina pending PROVEN EFFICACY — Incidence of disease (%) MARKET OPPORTUNITY Average of 13 trials, southern Europe Market Current Futu
Slide 11: Cedroz and Ecovelex add a combined €48m peak sales opportunity
CEDROZ · ECOVELEX Cedroz and Ecovelex add a combined €48m peak sales opportunity across nematicides and seed treatments Both products operate in underserved niches where regulatory restrictions on incumbents create structural white space Cedroz — Bionematicide Ecovelex — Seed treatment Biological bi
Slide 12: Mevalone pairs a three terpene active blend with Sustaine microencapsulation
MEVALONE® Mevalone® pairs a three terpene active blend with Sustaine® microencapsulation for broad disease control Product code 3AEY — commercial momentum building in new crop/disease combinations Product & active ingredients Formulation ▪ Unique Sustaine® Capsule Suspension (CS) ▪ Mevalone® (produc
Slide 13: Mevalone combines regulatory strength with grower-ready performance
MEVALONE® Mevalone® combines regulatory strength with grower-ready performance Eden retains full ownership of the regulatory dossier across all registered geographies Residue-free Five-region registration Food chain ready FRAC-recognised MoA performance Registered & commercialised in Multi-site mode
Slide 14: Biofungicide Mevalone Global presence
Biofungicide Mevalone® Global presence 14
Slide 15: Solura, sold as Cedroz by Eastman, brings encapsulated terpenes to nematode control
SOLURA® · CEDROZ Solura® — sold as Cedroz by Eastman — brings encapsulated terpenes to nematode control Registered in the US with Eden as holder; commercial across Southern EU, Morocco and Mexico Post-planting Encapsulated terpenes Direct knock-down No residues in harvest bionematicide For horticult
Slide 16: Regulatory approvals are building across all four key geographies
REGULATORY Regulatory approvals are building across all four key geographies — with a further wave pending EPA approval (Sep 2022) and California authorisation (Jan 2024) unlock the US commercial market. EU (EFSA) US (EPA) ▪ Active ingredients (eugenol, geraniol, thymol) renewal submitted to EFSA ▪
Slide 17: Four strategic pillars will drive the next phase of commercial growth
STRATEGY Four strategic pillars will drive the next phase of commercial growth Execution against all four is underway — the team, capabilities and regulatory pipeline are in place. 1 2 3 4 Commercial growth Business line diversification R&D and operations Strengthen the team ▪ Regulatory clearance i
Slide 18: A pipeline of six additional markets positions Eden for sustained revenue growth
OUTLOOK A pipeline of six additional markets positions Eden for sustained revenue growth beyond current products In-house GLP-ready labs reduce CRO dependency and compress development cycles. PIPELINE OPPORTUNITIES INNOVATION CAPACITY €38.2m peak Downy mildew France → S.EU → US (Eden) GLP-ready labo
Slide 19: IN020E is a residue-free bioinsecticide for multiple sucking pests
IN020E · TERPURE IN020E is a residue-free bioinsecticide for multiple sucking pests, built on Eden's terpene chemistry Foliar application; mechanical mode of action validated by IRAC What it is Terpure formulation ▪ EC formulation optimised for efficacy and safety ▪ Foliar bioinsecticide based on Ed
Slide 20: IN020E delivers broad, full lifecycle control of key sucking pests
IN020E · TERPURE IN020E delivers broad, full lifecycle control of key sucking pests Versatile residue-free tool for mites, thrips, whiteflies and aphids Broad pest coverage Full lifecycle control Cleaner than incumbents ▪ High efficacy against mites, thrips, ▪ Controls eggs, nymphs and adults of the
Slide 21: Bioinsecticide IN020E
Bioinsecticide IN020E IN020E Insecticide: versatile residue-free tool for multiple sucking pests 21
Slide 22: FUNG2 is a terpene-based fungicide in development for late blight
FUNG2 · EARLY STAGE FUNG2 is a terpene-based fungicide in development for late blight and other Oomycete diseases Field tested in Europe in 2024 and 2025, with rapid, rainfast protection under high disease pressure ▪ Cutting-edge terpene-based fungicide combining plant-derived actives with advanced
Slide 23: Two single active FUNG2 formulations are demonstrating efficacy against potato late blight
FUNG2 · EARLY STAGE Two single active FUNG2 formulations are demonstrating efficacy against potato late blight EU + UK field trials, 2024–2025 ERP054004 ERP054005 ▪ Application rate: 0.33 L/ha ▪ Application rate: 0.25 L/ha ▪ 1 active ingredient ▪ 1 active ingredient ▪ Formulation: CS (capsule suspen
Slide 24: Ecovelex is a bird repellent seed treatment protecting maize
ECOVELEX Ecovelex® is a bird repellent seed treatment protecting maize with Eden's terpene actives EU approval expected 2026; developed with Corteva since 2020; available in the rest of world today ▪ Bird repellent to protect maize seeds and plantlets ▪ Based on eugenol, geraniol and thymol, with Su
Slide 25: Eden offers a unique combination of proven products, deep IP and a growing regulatory footprint
Eden offers a unique combination of proven products, deep IP and a growing regulatory and commercial footprint Only UK AIM-quoted biopesticide company — sole opportunity to invest in a ‘pure-play’ €131m+ combined peak sales potential across four products 33-country footprint with US, France and Cent
Eden Research — 15 months to 31 March 2026 Earnings Presentation on 6ix